Back

Design and rationale of a phase 3 study to evaluate the efficacy and safety of nucresiran (ALN-TTRsc04) in patients with transthyretin amyloidosis with cardiomyopathy

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pharmacotherapy (4) Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
The spot urinary sodium determination in short-term decongestion therapy
Doctor A. Georgakopoulos (Veria, GR)
Abstract Slides Video
Presentation thumbnail
Patient-dependent factors limiting guideline-directed medical therapy in patients with heart failure with reduced left ventricular ejection fraction undergoing scheduled hospitalization
Doctor A. Galas (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Implementation of recommendations regarding pharmacotherapy optimization in patients with heart failure undergoing scheduled hospitalization - the HEROES study.
Doctor A. Galas (Warsaw, PL)
Abstract Slides Video
Presentation thumbnail
Reasons for underutilization of medical therapy for heart failure with reduced ejection fraction
Doctor K. Berge (Nordbyhagen, NO)
Abstract Slides Video
Presentation thumbnail
Efficiency of guideline-directed medical therapy in patients with acute decompensated heart failure and subclinical congestion at discharge.
Doctor N. Khutsishvili (Tbilisi, GE)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pharmacotherapy (4)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Design and rationale for MAGNITUDE, a phase 3, randomised, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy
thumbnail
Congress Presentation
Study design of the CARDIO-TTRansform cardiac magnetic resonance imaging substudy
thumbnail
Congress Presentation
Clinical presentation and treatment landscape of patients with transthyretin amyloidosis with cardiomyopathy: a real-world study in five European countries and Japan

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources